MYCO
MYCO

Mydecine Innovations Group Inc.

Associated Securities:
Status
Active
Issued & Outstanding52,567,458
Reserved for Issuance22,583,791
Currency
CSE Index

About

Mydecine Innovations Group Inc.

Listing date
October 06, 2023

Mydecine Innovations Group Inc. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.